Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude de phase 1b/2 sur le BGB-11417 en monothérapie et dans diverses combinaisons avec la dexaméthasone et le carfilzomib dans le myélome multiple

23 octobre 2026 mis à jour par: BeOne Medicines

Une étude de phase 1b/2 d'escalade de dose et d'expansion de cohorte pour déterminer l'innocuité et l'efficacité du BGB-11417 en monothérapie, en association avec la dexaméthasone et le carfilzomib/dexaméthasone chez les patients atteints de myélome multiple récidivant/réfractaire et t(11;14)

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14).

The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.

Aperçu de l'étude

Description détaillée

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Type d'étude

Interventionnel

Inscription (Estimé)

246

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Aachen, Allemagne, 52074
        • Recrutement
        • Universitaetsklinikum Aachen
      • Dresden, Allemagne, 01307
        • Recrutement
        • Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
      • Hamburg, Allemagne, 20251
        • Recrutement
        • Universitatsklinikum Hamburg Eppendorf
      • Würzburg, Allemagne, 97080
        • Recrutement
        • Universitatsklinikum Wurzburg
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australie, ACT 2605
        • Recrutement
        • Canberra Hospital
    • New South Wales
      • Kingswood, New South Wales, Australie, NSW 2747
        • Recrutement
        • Nepean Hospital
    • Victoria
      • Clayton, Victoria, Australie, VIC 3168
        • Recrutement
        • Monash Health
      • Fitzroy, Victoria, Australie, VIC 3065
        • Recrutement
        • St Vincents Hospital Melbourne
      • Melbourne, Victoria, Australie, VIC 3004
        • Recrutement
        • The Alfred Hospital
    • Western Australia
      • Perth, Western Australia, Australie, WA 6000
        • Recrutement
        • Royal Perth Hospital
      • Brasília, Brésil, 70200-730
        • Recrutement
        • Hospital Sirio Libanes Brasilia
      • Brasília, Brésil, 70390140
        • Recrutement
        • Instituto Dor de Pesquisa E Ensino Distrito Federal
      • Porto Alegre, Brésil, 90110-270
        • Recrutement
        • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
      • Salvador, Brésil, 41253-190
        • Recrutement
        • Hospital Sao Rafael (Rede Dor)
      • São Paulo, Brésil, 05652-900
        • Recrutement
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brésil, 01401-004
        • Recrutement
        • Instituto Dor de Pesquisa E Ensino Sao Paulo
      • São Paulo, Brésil, 01308-050
        • Recrutement
        • Hospital Sirio Libanes
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Recrutement
        • Cross Cancer Institute
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Recrutement
        • British Columbia Cancer Agency the Vancouver Centre
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Recrutement
        • Princess Margaret Cancer Centre
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100044
        • Recrutement
        • Peking University Peoples Hospital
      • Beijing, Beijing Municipality, Chine, 100000
        • Recrutement
        • Peking University Third Hospital
      • Beijing, Beijing Municipality, Chine, 100020
        • Recrutement
        • Beijing Chao Yang Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Chine, 400030
        • Recrutement
        • Chongqing Cancer Hospital
    • Fujian
      • Fuzhou, Fujian, Chine, 350001
        • Complété
        • Fujian Medical University Union Hospital
      • Xiamen, Fujian, Chine, 361003
        • Complété
        • The First Affiliated Hospital of Xiamen University
    • Guangdong
      • Guangzhou, Guangdong, Chine, 510060
        • Recrutement
        • Sun Yat Sen University Cancer Center
    • Hebei
      • Shijiazhuang, Hebei, Chine, 050000
        • Complété
        • The Second Hospital of Hebei Medical University
    • Henan
      • Zhengzhou, Henan, Chine, 450000
        • Recrutement
        • Henan Cancer Hospital
      • Zhengzhou, Henan, Chine, 450052
        • Actif, ne recrute pas
        • The First Affiliated Hospital of Zhengzhou University
    • Hubei
      • Wuhan, Hubei, Chine, 430022
        • Recrutement
        • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    • Hunan
      • Changsha, Hunan, Chine, 410013
        • Complété
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Chine, 210029
        • Recrutement
        • Jiangsu Province Hospital
    • Jiangxi
      • Nanchang, Jiangxi, Chine, 332000
        • Recrutement
        • The First Affiliated Hospital of Nanchang University Branch Xianghu
    • Liaoning
      • Shenyang, Liaoning, Chine, 110001
        • Recrutement
        • The First Hospital of China Medical University
    • Shandong
      • Qingdao, Shandong, Chine, 266000
        • Recrutement
        • Qingdao Municipal Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 200032
        • Recrutement
        • Affiliated Zhongshan Hospital of Fudan University
      • Shanghai, Shanghai Municipality, Chine, 200434
        • Complété
        • Shanghai Fourth Peoples Hospital Affiliated to Tongji University
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Chine, 301617
        • Recrutement
        • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
      • Tianjin, Tianjin Municipality, Chine, 300052
        • Complété
        • Tianjin Medical University General Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, Chine, 310003
        • Recrutement
        • The First Affiliated Hospital, Zhejiang University School of Medicine
    • Seoul Teugbyeolsi
      • GangnamGu, Seoul Teugbyeolsi, Corée du Sud, 06351
        • Recrutement
        • Samsung Medical Center
      • SeochoGu, Seoul Teugbyeolsi, Corée du Sud, 06591
        • Recrutement
        • The Catholic University of Korea, Seoul St Marys Hospital
      • SeodaemunGu, Seoul Teugbyeolsi, Corée du Sud, 03722
        • Recrutement
        • Severance Hospital Yonsei University Health System
      • Seoul, Seoul Teugbyeolsi, Corée du Sud, 03080
        • Recrutement
        • Seoul National University Hospital
      • SongpaGu, Seoul Teugbyeolsi, Corée du Sud, 05505
        • Recrutement
        • Asan Medical Center
      • Barcelona, Espagne, 08036
        • Actif, ne recrute pas
        • Hospital Clinic de Barcelona
      • Poitiers, France, 86000
        • Complété
        • Chu de Poitiers Site de La Mileterie
      • Alexandroupoli, Grèce, 68100
        • Recrutement
        • University Hospital of Alexandroupolis
      • Athens, Grèce, 115 28
        • Recrutement
        • General Hospital of Athens Alexandra
      • Ancona, Italie, 60020
        • Recrutement
        • Azienda Ospedaliera Universitaria Delle Marche
      • Bari, Italie, 70124
        • Recrutement
        • Azienda Ospedaliera Policlinico Di Bari
      • Bologna, Italie, 40138
        • Recrutement
        • Policlinico Sorsola Malpighi, Aou Di Bologna
      • Meldola, Italie, 47014
        • Recrutement
        • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
      • Milan, Italie, 20141
        • Recrutement
        • Istituto Europeo Di Oncologia
      • Headington, Royaume-Uni, OX3 7LE
        • Recrutement
        • Oxford University Hospitals Nhs Trust Churchill Hospital
      • London, Royaume-Uni, NW1 2PG
        • Recrutement
        • University College Hospital
      • Sutton, Royaume-Uni, SM2 5PT
        • Recrutement
        • Royal Marsden Nhs Foundation Royal Marsden Hospital
      • Singapore, Singapour, 119074
        • Recrutement
        • National University Hospital Singapore
    • Alabama
      • Birmingham, Alabama, États-Unis, 35294-0004
        • Recrutement
        • University of Alabama At Birmingham Hospital
    • California
      • Duarte, California, États-Unis, 91010-3012
        • Recrutement
        • City of Hope National Medical Center
      • Irvine, California, États-Unis, 92618-2377
        • Recrutement
        • City of Hope Irvine Lennar
    • Florida
      • Miami, Florida, États-Unis, 33136-2107
        • Recrutement
        • University of Miami
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322-1013
        • Recrutement
        • Emory University Winship Cancer Center
    • Illinois
      • Chicago, Illinois, États-Unis, 60637-1443
        • Recrutement
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02114
        • Complété
        • Massachusetts General Hospital
    • Missouri
      • St Louis, Missouri, États-Unis, 63110-1010
        • Recrutement
        • Washington University School of Medicine
    • New Jersey
      • Hackensack, New Jersey, États-Unis, 07601-1915
        • Recrutement
        • Hackensack University Medical Center
    • New York
      • New York, New York, États-Unis, 10065-6800
        • Recrutement
        • Memorial Sloan Kettering Cancer Center Mskcc
    • Ohio
      • Columbus, Ohio, États-Unis, 43210-1240
        • Recrutement
        • The James Cancer Hospital and Solove Research Institute At Ohio State University
    • Utah
      • Salt Lake City, Utah, États-Unis, 84112-5550
        • Recrutement
        • Huntsman Cancer Institute
    • Washington
      • Seattle, Washington, États-Unis, 98195
        • Recrutement
        • University of Washington
    • Wisconsin
      • Madison, Wisconsin, États-Unis, 53792-0001
        • Recrutement
        • University of Wisconsin Carbone Cancer Center
      • Milwaukee, Wisconsin, États-Unis, 53226-3522
        • Recrutement
        • Medical College of Wisconsin

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

  2. A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)

  3. Measurable disease defined as:

    i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio

  4. Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.

    i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM.

    ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy.

    1. In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
    2. Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator.
    3. Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD
  5. Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory

    a. fresh bone marrow aspirate sample must be collected at screening and sent to central laboratory for t(11;14) FISH testing.

  6. Adequate organ function defined as:

    1. Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted)
    2. Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions
    3. Absolute neutrophil count (ANC) ≥ 1000/mm^3 within 7 days before first dose of study treatment
    4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ≤ 2.0 x ULN N (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)

Exclusion Criteria:

  1. Participant has any of the following conditions:

    1. Non secretory MM (Serum free light chains < 10 mg/dL)
    2. Solitary plasmacytoma
    3. Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or > 2.0 x 109/L circulating plasma cells by standard differential)
    4. Waldenström macroglobulinemia (WM)
    5. Amyloidosis.
    6. Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome
    7. Chronic respiratory disease that requires continuous oxygen
  2. Significant cardiovascular disease, including but not limited to:

    1. Myocardial infarction ≤ 6 months before screening
    2. Ejection fraction ≤ 50%
    3. Unstable angina≤ 3 months before screening
    4. New York Heart Association Class III or IV congestive heart failure
    5. History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
    6. Heart rate-corrected QT interval > 480 milliseconds based on Fridericia's formula
    7. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
    8. Uncontrolled hypertension at screening, defined as systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg by ≥ 2 consecutive measurements. Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
  3. Known infection with human immunodeficiency virus (HIV)

  4. Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows:

    1. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity < 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation.
    2. Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity < 15 IU/mL).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part 1 Dose Escalation

Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.

Administered orally daily

Autres noms:
  • BGB-11417

Once weekly either orally or intravenously

Administered intravenously weekly

Administered subcutaneously weekly

Administered orally daily

Expérimental: Part 2 Cohort Expansion

There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab

Administered orally daily

Autres noms:
  • BGB-11417

Once weekly either orally or intravenously

Administered intravenously weekly

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Partie 1 et 2: Nombre de participants signalant un ou plusieurs événements indésirables émergents du traitement (TEAES), événements indésirables graves (ESA), événements indésirables conduisant à l'arrêt et aux événements indésirables de l'intérêt spécial (AESE).
Délai: Jusqu'à 30 jours après la dernière dose de médicament à l'étude
Jusqu'à 30 jours après la dernière dose de médicament à l'étude
Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
Délai: Up to 28 days

DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol.

Up to 28 days
Part 2: Overall response rate (ORR) as Assessed by Investigator
Délai: Approximately 4 years

Defined as the percentage of participants who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria

Approximately 4 years
Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator
Délai: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]

Defined as the percentage of participants with a documented VGPR or better (including sCR, CR, and VGPR)

Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator
Délai: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

defined as the percentage of participants with a documented CR or sCR

Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Partie 1: Aire sous la courbe de concentration plasmatique Temps de courbe 0 à la dernière concentration mesurable (auclast) après une seule dose de sonrotoclax
Délai: Cycle 1 (chaque cycle est jusqu'à 28 jours)
Cycle 1 (chaque cycle est jusqu'à 28 jours)
Partie 1: Concentration plasmatique maximale observée (CMAX) après une seule dose de sonrotoclax
Délai: Cycle 1 (chaque cycle est jusqu'à 28 jours)
Cycle 1 (chaque cycle est jusqu'à 28 jours)
Partie 1: Il est temps d'atteindre Cmax (Tmax) après une seule dose de Sonrotoclax
Délai: Cycle 1 (chaque cycle est jusqu'à 28 jours)
Cycle 1 (chaque cycle est jusqu'à 28 jours)
Partie 1: À l'état d'équilibre: AUC Last, SS
Délai: Cycle 2 (chaque cycle représente jusqu'à 28 jours)
Cycle 2 (chaque cycle représente jusqu'à 28 jours)
Partie 1: À l'état d'équilibre: Cmax, SS
Délai: Cycle 2 (chaque cycle est jusqu'à 28 jours)
Cycle 2 (chaque cycle est jusqu'à 28 jours)
Partie 1: À l'état d'équilibre: concentration plasmatique auge (ctrough) SS
Délai: Cycle 2 (chaque cycle est jusqu'à 28 jours)
Cycle 2 (chaque cycle est jusqu'à 28 jours)
Partie 1: À l'état d'équilibre: il est temps d'atteindre Cmax (Tmax, SS)
Délai: Cycle 2 (chaque cycle est jusqu'à 28 jours)
Cycle 2 (chaque cycle est jusqu'à 28 jours)
Part 2: Time to response (TTR) as Assessed by Investigator
Délai: Approximately 4 years

TTR is defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to first documentation of response of Partial Response (PR) or better

Approximately 4 years
Part 2: Duration of response (DOR) as Assessed by Investigator
Délai: Approximately 4 years

DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurs first. DOR will be analyzed only for patients who have achieved an overall response of at least PR. The distribution of DOR will be summarized by the Kaplan-Meier method.

Approximately 4 years
Part 2: Progression-free survival (PFS) as Assessed by Investigator
Délai: Approximately 4 years

PFS is defined as time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts) to the first documentation of disease progression or death, whichever occurs first

Approximately 4 years
Part 2: Overall survival (OS) as Assessed by Investigator
Délai: Approximately 4 years

OS defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to the date of death due to any cause

Approximately 4 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 septembre 2021

Achèvement primaire (Estimé)

1 novembre 2026

Achèvement de l'étude (Estimé)

1 novembre 2026

Dates d'inscription aux études

Première soumission

7 juillet 2021

Première soumission répondant aux critères de contrôle qualité

20 juillet 2021

Première publication (Réel)

22 juillet 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

26 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

23 octobre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Délai de partage IPD

See plan description

Critères d'accès au partage IPD

See plan description

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner